Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.46 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 3/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2195589 | 0.99 | HRH3 (0.54) | HRH3CYP2D6NFE2L2GRM2LTA4H | |
| SCHEMBL2196194 | 0.78 | GPR119 (0.48) | HRH3 | |
| SCHEMBL2195417 | 0.77 | NFE2L2 (0.55) | HRH3NFE2L2GRM2HPGD | |
| SCHEMBL12420613 | 0.76 | HRH3 (0.51) | HRH3CYP2D6 | |
| SCHEMBL13806601 | 0.76 | HRH3 (0.55) | HRH3LTA4HCXCR4ACHE | |
| SCHEMBL12420777 | 0.76 | DRD3 (0.46) | HRH3CYP2D6NFE2L2KCNH2ITGB3 | |
| Hydrochloric Acid SCHEMBL2196646 | 0.75 | HRH3 (0.50) | HRH3CYP2D6KCNH2 | |
| SCHEMBL23944117 | 0.75 | HRH3 (0.49) | HRH3LTA4HKCNH2CXCR4 | |
| SCHEMBL12420874 | 0.73 | CXCR4 (0.50) | HRH3NFE2L2CXCR4ACHE | |
| SCHEMBL13806526 | 0.73 | FAAH (0.49) | HRH3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | FAAH, FAAH2, UTS2R | HRH3 94/4885CYP2D6 3951/4885NFE2L2 1770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.